

Fig. 4. Ultrastructural alterations in *Borrelia burgdorferi* after being exposed to a ciprofloxacin concentration of 1 µg/mL. (a) Electron-dense swelling of the protoplasmic cylinder complex. Phosphotungstate stain,  $\times 97,000$ , fixed. Bar = 0.1 µm.




Fig. 5. Ultrastructural alterations in *Borrelia burgdorferi* after being exposed to a ciprofloxacin concentration of 2 µg/mL. (a) Debris of the protoplasmic cylinder complex (arrows). Phosphotungstate stain,  $\times 97,000$ , fixed. Bar = 0.1 µm.



Fig. 6. Ultrastructural alterations in *Borrelia burgdorferi* after being exposed to a ciprofloxacin concentration of 3 µg/mL. (a) Debris of fragments of the outer envelope. Phosphotungstate stain,  $\times 90,000$ , unfixed. Bar = 0.2 µm.



with ciprofloxacin concentrations of 1 µg/mL (MIC) and more.

#### DISCUSSION

The MIC of 1 µg/mL for our *Borrelia burgdorferi* strains was comparable to that found by investigators of other studies (5, 6). Our results confirm that *Borrelia burgdorferi* shows some moderate susceptibility to ciprofloxacin.

The ultrastructural morphology of our untreated *Borrelia burgdorferi* isolates (Fig. 1) corresponded with former morphological descriptions by Barbour and Hayes (13), Hovind-Hougen and coworkers (12, 14), and Hayes and Burgdorfer (15). Also, the measurements for length and diameter as well as the number of flagella were characteristic for *Borrelia* species (12–15).

Both *Borrelia burgdorferi* isolates examined in this study exhibited temperature bacteriophages showing an A-1 morphology that were incapable of infecting subinhibitory ciprofloxacin concentrations (Fig. 2). The phage-causing *Borrelia burgdorferi* cells showed severe ultrastructural alterations of their morphology (1), which completely differed from the ciprofloxacin effects on borreliae observed at concentrations of 1 to 8 µg/mL. Induction of prophages occurred only at subinhibitory ciprofloxacin concentrations, presumably as production and release of bacteriophages depend on an undisturbed metabolism of the host organism. In our former study (1), we examined two *Candidatus* *Borrelia* and one tick isolate for the presence of bacteriophages. All lysogenic borreliae contained A-1 bacteriophages, the first *sk1* isolate in addition a B-1 bacteriophage (1).

Besides these phage-induced morphological alterations of borrelial cells, other ciprofloxacin-induced ultrastructural changes could be observed at concentrations of 1 µg/mL (MIC) and more. The normal cell division was considerably disturbed at a ciprofloxacin concentration of 1.25 µg/mL (MIC). In *Borrelia burgdorferi* exposed by brief transverse fission (Fig. 3), cell division is started by constriction of the peptidoglycan layer in the middle of a long cell (13). Obviously, as a result of the irregular constriction of the peptidoglycan layer in the periphery of abnormal elongated borrelial cells, very short cell fragments became visible (Fig. 3). The damaging effect of ciprofloxacin first led to swellings (Fig. 4a), after that to membrane defects (Fig. 5a), and finally to the disruption of the protoplasmic cylinder complex (Fig. 6).

At ciprofloxacin concentrations ranging from 0.125 to 2 µg/mL, large spherical forms filled with remnants of the protoplasmic cylinder complex described before (Fig. 7) were observed (13, 15), but the significance and function of such structures are still unknown. In comparison with the results of Voigt and Zeiler (2), Elliott et al. (3), and Rodgers et al. (4), who demonstrated that ciprofloxacin primarily affected areas located in the cell wall of gram-negative and gram-positive bacteria, we found severe morphological alterations concerning mainly the protoplasmic cylinder complex of *Borrelia burgdorferi*.

In contrast to penicillin-treated borreliae, which showed morphological alterations even at subinhibitory concentrations (Sobczyk et al., 1991), *Morphology of Borrelia burgdorferi* exposed to benzylpenicillin. Infection, (in press), in nonlyticogenic borreliae, no ciprofloxacin-induced changes were visible at concentrations below the MIC.

This may be a further explanation why ciprofloxacin does not show the same *in vivo* efficacy (Meisel C, personal

#### 40 SCHALLER AND NEUBERT

communication) in comparison to the  $\beta$ -lactam antibiotics preferentially used in treatment of early Lyme-borreliosis (5, 6).

The authors thank Mrs. H. Jauschko for her excellent technical assistance.

Reprint requests: Martin Schaller, M.D., Department of Dermatology, Ludwig-Maximilians-University, Frauenlobstr. 9-11, 80337 Munich, Federal Republic of Germany.

#### REFERENCES

1. Neubert U, Schaller M, Jauschko B, Stolz W, Schmeleg H. Bacteriophages induced by ciprofloxacin in a *Borrelia burgdorferi* skin isolate. *Zentralblatt Bakteriologie Hygiene* 279:307–315, 1993.
2. Voigt WM, Zeiler H. Influence of ciprofloxacin on the ultrastructure of gram-negative and gram-positive bacteria. *Arzneimittelforschung/Drug Res* 35 (H), Nr. 10:600–603, 1985.
3. Elliott TSJ, Sheldon A, Greenwood D. The response of *Escherichia coli* to ciprofloxacin and norfloxacin. *J Med Microbiol* 23:1–81, 1986.
4. Rodgers FG, Trisnabas O, Elliott TSJ. The effect of antibiotics that inhibit cell-wall protein, and DNA synthesis on the growth and morphology of *Legionella pneumophila*. *J Med Microbiol* 31:37–44, 1990.
5. Prendergast J, Wilkite B, Schler B, Holmberger M, Süß E. *In vitro* and *in vivo* susceptibility of *Borrelia burgdorferi*. *Eur J Clin Microbiol* 6:24–42, 1987.
6. Levin JM, Nelson JA, Segel J, Hartson B, Benson CA, Steele P. *In vitro* susceptibility of *Borrelia burgdorferi* to 11 antimicrobial agents. *Antimicrob Agents Chemother* 37:1444–1446, 1993.
7. Basilio AG. Isolation and characterization of Lyme disease spirochetes. *Yale J Biol Med* 57:521–525, 1984.
8. Johnson RC, Kodner CL, Russel ME. Vaccination of hamsters against experimental infection with *Borrelia burgdorferi*. *Zentralblatt Bakteriologie Hygiene A* 263:45–46, 1986.
9. Rossen L, Hovind-Hougen D, Sørensen TG. Polymerase chain reaction analysis identical to the *in vitro* test of *Borrelia burgdorferi*. *J Clin Microbiol* 29:524–532, 1991.
10. Wiesnicki R, Koch ON, Neubert U, Goebel U, Volksenad M. Detection of subtype-specific nucleotide sequence differences in a *Borrelia burgdorferi* specific gene segment by analysis of conformational variation of cRNA molecules. *Med Microbiol Immunol* 223:239–246, 1983.
11. Baranton G, Postic D, Saint Girons I, Bocchia P, Pisaretti JC, Assous M, Grenouillet PAD. Delicacy of *Borrelia burgdorferi* sensu stricto, *Borrelia garinii* sp. nov., and group VS 461, associated with Lyme borreliosis. *Int J System Bacteriol* 42:378–383, 1992.
12. Hovind-Hougen K. Ultrastructure of spirochetes isolated from Ixodes ricinus and Ixodes dammini. *Yale J Biol Med* 57:543–548, 1984.
13. Baranton G, Hayes SF. Biology of *Borrelia* Species. In *Microbiological Review*. Washington, DC, American Society for Microbiology, Vol. 50, 1986, pp. 381–400.
14. Hovind-Hougen K, Asbrink B, Siersbold G, Sirec AC, Hovmark A. Ultrastructural differences among spirochetes isolated from patients with Lyme disease, relapsing fever, and from Ixodes ricinus. *Zentralblatt Bakteriologie Hygiene* A 264:103–111, 1986.
15. Hayes SF, Burgdorfer W. Ultrastructure of *Borrelia burgdorferi*. In Weber K, Burgdorfer W, eds. *Aspects of Lyme Borreliosis*. Berlin, Springer-Verlag, 1992, pp. 29–43.
16. Ackermann HW. *The genus Borrelia and its spiroplasmas*. In: Laskin AL, Lechavalier HA, eds. *Handbook of Microbiology*. Cleveland, OH, CRC Press, vol. 1, 1973, pp. 573–576.
17. Ackermann HW. Tailed bacteriophages: listed by morphological groups. In: Laskin AL and Lechavalier HA, eds. *Handbook of Microbiology*. Cleveland, OH, CRC Press, vol. 1, 1973, pp. 579–607.
18. Ackermann HW, Andriole A, Berthium L, Jones LA, Mayo A, Vidaver AK. Guidelines for bacteriophage characterization. *Adv Virus Res* 23:1–24, 1978.